Novo Nordisk A/S
NONOF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $290 | $232 | $177 | $141 |
| % Growth | 25% | 31.3% | 25.7% | – |
| Cost of Goods Sold | $45 | $36 | $28 | $24 |
| Gross Profit | $246 | $196 | $149 | $117 |
| % Margin | 84.7% | 84.6% | 83.9% | 83.2% |
| R&D Expenses | $48 | $32 | $24 | $18 |
| G&A Expenses | $5 | $5 | $4 | $4 |
| SG&A Expenses | $67 | $62 | $51 | $41 |
| Sales & Mktg Exp. | $62 | $57 | $46 | $37 |
| Other Operating Expenses | $2 | -$0 | -$1 | -$0 |
| Operating Expenses | $118 | $94 | $74 | $58 |
| Operating Income | $128 | $103 | $75 | $59 |
| % Margin | 44.2% | 44.2% | 42.3% | 41.7% |
| Other Income/Exp. Net | -$1 | $2 | -$6 | $0 |
| Pre-Tax Income | $127 | $105 | $69 | $59 |
| Tax Expense | $26 | $21 | $14 | $11 |
| Net Income | $101 | $84 | $56 | $48 |
| % Margin | 34.8% | 36% | 31.4% | 33.9% |
| EPS | 22.68 | 9.34 | 12.26 | 10.4 |
| % Growth | 142.8% | -23.8% | 17.9% | – |
| EPS Diluted | 22.64 | 9.31 | 12.22 | 10.37 |
| Weighted Avg Shares Out | 4 | 4 | 5 | 5 |
| Weighted Avg Shares Out Dil | 4 | 4 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $0 | $0 |
| Interest Expense | $2 | $1 | $0 | $0 |
| Depreciation & Amortization | $9 | $6 | $5 | $5 |
| EBITDA | $137 | $111 | $77 | $65 |
| % Margin | 47.3% | 47.8% | 43.4% | 46% |